Skip to main content
. 2021 Nov 20;24(11):784–789. [Article in Chinese] doi: 10.3779/j.issn.1009-3419.2021.102.42

表 2.

类癌相关免疫治疗临床试验及回顾性研究

ICIs related clinical trials and retrospective study of immunotherapy for carcinoid

Research Phase n Drugs ORR mPFS (mon) mOS (mon) Identifier
spa: Spartalizumab; AC: atypical carcinoid.
KEYNOTE-028[35] Ib 107 pem 12.0% 5.6 21.1 NCT02054806
Janice et al[36] Retrospective 25 pem 12.0% 5.6
Yao et al[38] II 30 spa 16.7% NCT02955069
CA209-538[39] II 29 ipi+nivo 24.0% (AC: 33.0%) 4.8 14.8 NCT02923934